Europe Antibody Drug Conjugates Market: Industry Analysis and Forecast (2024-2030)

Europe Antibody Drug Conjugates Market Overview

Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

 

The Report analyses the current market trends and emerging technologies that influenced the market growth in the European Antibody Drug Conjugates Market. The report focuses on the strategic partnerships, mergers, and acquisitions that are held in 2023 and are expected to happen during the forecast period. The report also considers the impact of changing lifestyles on the growth of the market in Europe Antibody Drug Conjugates Market. In-depth analysis of market dynamics that includes drivers, trends, opportunities, restraints, and challenges that impact the market growth in Europe. The Report is intended to provide market and strategic insights about the market to help investors get valuable insights into the market.

 

According to STELLAR Analysis, The number of people being diagnosed with cancer by 2030 in EU and EFTA countries is estimated to increase by 21% compared to 2020.

 

To get more Insights: Request Free Sample Report

 

Europe Antibody Drug Conjugates Market dynamics

Driving Forces and Growth Trends in Europe's Antibody-Drug Conjugate Market

The antibody-drug conjugate (ADC) industry is witnessing a development in the variety of conjugation techniques, linker chemistry, and payloads being used, moving beyond traditional tubulin inhibitors to include novel mechanisms of action that have propelled the market growth in Europe. ADCs have attracted significant interest as highly targeted and potent medicines in many therapeutic areas.  Population aging has led to a big increase in the number of people dying from cancer by 32% by 2030.

 

Increased investment and collaborations by key market players for the development of Antibody-drug conjugates have accelerated the market growth in Europe. Collaboration and partnership among market players, increasing focus on the development of new ADCs, and frequent approval of new ADCs by the FDA are the major factors driving the market growth. Strong products in clinical trials and increased use of ADCs as combination therapy are likely to drive market growth in the coming years.

 

Rising cancer incidences are primarily leading to the increasing demand for innovative cancer treatments. According to STELLAR Analysis, it is estimated to increase 21% in new cancer cases by 2030. The rising prevalence of breast cancer coupled with increased approvals for the ADCs for breast cancer treatment are some of the factors driving the market.

 

Europe Antibody Drug Conjugates Market Challenges

Challenges and Regulatory Hurdles in Europe's Antibody-Drug Conjugate Market

Limited access to healthcare, inadequate screening programs, and a lack of awareness about cancer prevention contribute to a higher proportion of late-stage diagnoses and poorer outcomes.

 

ADCs are highly complex and structurally heterogeneous, typically containing numerous product-related species. ADCs are often considered a new generation of highly hazardous and toxic pharmaceutical products. The unique nature of ADC presents challenges in its large-scale production of Antibody-drug Conjugate.

 

The Rules and Regulations set by the European government that had implications on the Antibody drug Conjugate have created a barrier to market growth. For Instance, ADC manufacturing requires proper facilities that strictly follow the criteria and guidelines of cGMP-standard bio-macromolecule production, these facilities are extremely stringent about aseptic production and it need to be operated under an occupational exposure limit (OEL) below 50 ng/m3.

 

The development of the Antibody drug Conjugate involves extensive research, clinical trials, and manufacturing processes that require large expenditures. Financial burden limits the number of companies investing in ADC development. In addition, the risk of failure of clinical trials increases overall costs. The high development costs associated with ADCs are a significant challenge, and cost-effective strategies are sought without compromising quality and safety.

 

Europe Antibody Drug Conjugates Market Segment Analysis

Based on Product Type, the Adcetris segment holds the highest market share and is expected to dominate Europe during the forecast years. Adcetris is a cancer medicine used to treat adults with certain lymphomas (cancers of lymphocytes, white blood cells that are part of the immune system). It is used when the cancer cells have a protein called CD30 on their surface (CD30-positive)

 

• In October 2023, the European Commission approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with previously untreated CD30+ stage III Hodgkin lymphoma in combination.

 

Based On Application, Breast Cancer hold the largest share in Europe with a growing CAGR of a 8.93 % during the forecast year. Factors contributing to breast cancer incidence and mortality in women include the implementation of organized breast cancer screening activities and the different prevalence and distribution are the major risk factors. For example, a high maternal age at first birth, a low number of births, and lack of breastfeeding are factors increasing breast cancer risk. The estimated incidence and mortality rates of breast cancer in women varied around twofold across EU27 countries, up to 190 new cases and 45 deaths per 100,000 women. Breast cancer mortality rates in women are decreasing in most European countries, especially Northern and Western Europe. These favorable trends reflect the advances in earlier detection and improvements in treatment such as Antibody drug conjugate.

Europe Antibody Drug Conjugates Market Regional Analysis

Germany dominated the market with the majority share and is expected to grow with a growing CAGR of a 9.20 % during the forecast period. The rising prevalence of cancer in Germany has led to propelling the market growth. Developed countries tend to have higher overall cancer rates owing to several factors, including aging populations and lifestyle choices. For example, countries in Western Europe, consistently report higher cancer incidence rates. These countries also tend to have more advanced healthcare systems, which contribute to better cancer detection and reporting.

 

France is expected to witness substantial growth in the Antibody-drug conjugate market with a growing CAGR of 8.55% during the forecast years. The Antibody drug conjugate industry has witnessed substantial growth, driven by advancements in antibody engineering, linker technology, and payload selection, resulting in a robust pipeline of promising ADC candidates across various cancer types.

 

The United Kingdom is the fastest-growing country and is expected to dominate Europe during the forecast period owing to the Rapid advancements in antibody engineering that have significantly contributed to the growth of the ADC market. The development of high-affinity antibodies, novel linker technologies, and more efficient conjugation methods have enhanced the stability and efficacy of ADCs. These advancements have allowed for better control over drug-antibody ratios and improved target specificity, leading to the development of next-generation ADCs with enhanced therapeutic potential in the country.

 

France, Spain, Russia, Poland, Netherlands, etc., are expected to witness steady growth in the Antibody-drug conjugate Market owing to an increased prevalence of cancer and rising awareness of cancer treatments.

Europe Antibody Drug Conjugates Market Competitive Landscape

Competitive Landscape focuses on several aspects such as mergers, acquisitions, and Recent developments in the Market Leaders. The Report has covered an in-depth analysis of the key players present in the market to provide insights to the stakeholders.

 

• In December 2023, Roche signed an agreement for the acquisition of US-based Company Carmot Therapeutics in a deal valued at $2.7bn. Roche enters into a definitive merger agreement to acquire Carmot Therapeutics, whose portfolio includes three clinical-stage assets with best-in-class potential in obesity and diabetes Carmot Therapeutics’ research and development portfolio of clinical-stage incretins has great potential to treat obesity, diabetes, and potentially other diseases both as stand-alone medicines and in combination with Roche’s in-house assets.
• In March 2024, AstraZeneca acquired Fusion to accelerate the development of next-generation radio conjugates to treat cancer. The acquisition brings new expertise and pioneering R&D, manufacturing, and supply chain capabilities in actinium-based RCs to AstraZeneca.

 

	Europe Antibody Drug Conjugate Market
Market Size in 2023	USD 4.10 Bn.
Market Size in 2030	USD 7.43 Bn.
CAGR (2024-2030)	8.87 %
Historic Data	2018 - 2022
Base Year	2023
Forecast Period	2024-2030
Segment Scope	By Product Type Adcetris  Kadcyla
	By Application Blood Cancer Breast Cancer Ovary Cancer Lung Cancer Skin Cancer Brain Tumor Other
	By Technology Cleavable Linker Non-cleavable Linker
	By End User Hospitals and Speciality Cancer Centers Biotechnology and Pharmaceutical Companies
Country Scope	Germany United Kingdom Spain France Italy Belgium Sweden Poland Russia

 

Europe Antibody Drug Conjugates Market Key Players

1. Berlin Chemie
2. Stada Arzneimittel
3. Sartorius AG
4. Fresenius Kabi
5. B. Braun
6. Phoenix Pharmahandel
7. Bayer
8. GSK
9. F. Hoffmann-La Roche Ltd
10. AstraZeneca PLC
11. Novartis AG
12. GlaxoSmithKline plc
13. Bayer AG
14. Pfizer Inc.
15. Sanofi S.A.
16. Merck KGaA
17. Boehringer Ingelheim International GmbH